ClinicalTrials.gg
RecruitingNCT04612335Updated May 22, 2024

Device-based Rate Versus Rhythm Control in Symptomatic Recent-onset Atrial Fibrillation (RACE 9 OBSERVE-AF)

An interventional study of Rate control and Pharmacological or electrical cardioversion in Atrial Fibrillation, sponsored by Maastricht University Medical Center. Recruiting at 14 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Atrial Fibrillation by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Maastricht University Medical Center.

Planned enrollment
3rd of 11
490 · median 150
Started
2020
the only one that year
No phase
10 of 16
2 open now
Registered
12th of 16
by date

Among the 16 studies in Atrial Fibrillation by Maastricht University Medical Center, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 10 with no phase, and was the 12th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 16 studies in Atrial Fibrillation by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by Maastricht University Medical Center, or all of them as a file.
02

Study summary

Continuous heart rhythm monitoring elucidated the recurrent and transient nature of recent-onset atrial fibrillation (AF). The RACE7 ACWAS showed that a wait-and-see approach (WAS) in patients with recent-onset AF (rate control for symptom relief followed by delayed cardioversion if needed \<48h) allows spontaneous conversion to sinus rhythm in 69% of patients, obviating active cardioversion. Recurrences within one month were seen in 30% of patients in both groups, i.e. the initially chosen strategy did not affect the recurrence pattern. Considering the latter, it remains unclear whether cardioversion is needed at all, especially since cardioversion strategy does not seem to affect behaviour of the arrhythmia over time. Instead of cardioversion a watchful-waiting rate control strategy may be appropriate as initial strategy. This allows observing the electrical and clinical behavior of arrhythmia, providing a solid basis for comprehensive and effective early rhythm control. This study is a multi-center clinical randomized controlled trial to show non-inferiority of watchful-waiting with rate control versus routine care in terms of prevalence of sinus rhythm at 4 weeks follow-up, using a novel telemonitoring infrastructure to guide rate control during follow-up.

Read the detailed description

Until recently standard of care for patients with recent-onset atrial fibrillation (AF) was early cardioversion. This has just been expanded with a delayed cardioversion approach. However, considering the recurrent and transient nature of AF, cardioversion might not be needed at all and rate control medication might be sufficient to accomplish spontaneous conversion to sinus rhythm. The aim of this trial is to evaluate effectiveness (presence of sinus rhythm) of a watchful-waiting approach, i.e. symptom reduction through rate-control medication and monitoring until spontaneous conversion is achieved compared to routine care, consisting of either early or delayed cardioversion. The trial is a multicentre prospective, randomized, open label, non-inferiority trial comparing the interventional watchful-waiting approach to routine care (control).The primary endpoint (presence of sinus rhythm), will be assessed after 4 weeks. The total follow-up time is 1 year.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Atrial fibrillation
  • Cardiac arrhythmia
  • Cardioversion
  • Electrical cardioversion
  • Watchful waiting
  • Wait-and-see
  • Telemonitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • with atrial fibrillation
  • Duration of the current AF episode \<36 hours
  • Symptoms due to atrial fibrillation
  • Age > 18 years
  • Able and willing to sign
  • Able and willing to use telemetric rhythm recorder

Exclusion criteria

Exclusion Criteria:

  • History of persistent AF (episode of AF lasting more than 48 hours and terminated by cardioversion)
  • Deemed unsuitable for participation by attending physician
  • Hemodynamic instability (heart rate >170 bpm, systolic blood pressure \<100 mmHg)
  • Acute heart failure
  • Signs of myocardial infarction
  • History of syncope of unexplained origin
  • History of untreated Sick Sinus Syndrome
  • History of untreated Wolff-Parkinson-White syndrome
  • Currently enrolled in another clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
490 participants (estimated)

Study arms

  • Experimental
    Watchful waiting

    the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate \<110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.

    Other: Rate control

  • Other
    Routine care

    Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.

    Other: Pharmacological or electrical cardioversion

Interventions

  • OtherRate control

    Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.

  • OtherPharmacological or electrical cardioversion

    Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.

06

What researchers measure

Primary outcomes

  1. Presence of sinus rhythm

    Sinus rhythm documented on a 12-lead ECG

    Time frame: 4 weeks after inclusion

Secondary outcomes

  1. Implementation of the telemonitoring infrastructure

    e.g. use of telemonitoring infrastructure during the 4 weeks follow up, accuracy of alert system

    Time frame: 4 weeks

  2. MACCE: major cardiovascular mortality and cardiovascular and cerebrovascular events

    e.g. hospitalisation for stroke, myocardial infarction

    Time frame: 1 year

  3. AF recurrences/AF progression

    e.g. number of AF recurrences, progression to persistent AF

    Time frame: 4 weeks and 1 year

  4. Cost-effectiveness

    The costs and cost-effectiveness of the new approach will be determined and compared to the costs and cost-effectiveness of routine care.

    Time frame: 1 year

  5. Questionnaires on quality of life (SF-36)

    Questionnaires on quality of life (e.g. SF-36), will be used to assess whether there are differences between the two arms. The SF-36 will be evaluated according to recommendations; scores will be recoded on a scale of 0-100 and averaged. Higher scores indicate better quality of life.

    Time frame: 1 year

  6. Patient reported experiences

    A questionnaire on patient reported experiences with the telemonitoring device will be used to assess whether there are differences between the two arms. There will be both positively orientated, and negatively orientated questionnes which have to be rated on a scale of 1-5.

    Time frame: 1 year

  7. Rate and rhythm control interventions (number of)

    Alert- and patient-triggered

    Time frame: 4 weeks

  8. Rhythm control interventions

    Number of participants with cardioversion, catheter ablation

    Time frame: 1 year

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All elements from the CRF matching a future project's CRF may be provided for an aggregated analysis.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Well after publication of main paper

Access criteria: Please contact principal investigator or study chair.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Jun 2024, 43 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 43 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Nov 2, 2020
StartActual
Nov 16, 2020
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2025
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04612335
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Dutch Heart Foundation, Netherlands Organisation for Scientific Research
Responsible party
Sponsor
First posted
Nov 2, 2020
Start date
Nov 16, 2020
Primary completion
Jun 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
May 22, 2024

Study contacts

Rachel MJ van der Velden, MD
Contact
rachel.vander.velden@mumc.nl
31433876885
Nikki AH Pluymaekers, MD
Contact
nikki.pluymaekers@mumc.nl
31433875119
Harry JG Crijns, MD, PhD
study chair · Head of cardiology department, Maastricht University Medical Center
Dominik Linz, MD, PhD
principal investigator · Head of cardiac electrophysiology, Maastricht University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion